drugset / Trial / NCT00336310

A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients

NCT00336310

Phase 4 Unknown 50 enrolled National Cheng-Kung University Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether a new-brand of repaglinide is effective in the treatment of type 2 diabetes patients.

Timeline

Start
2006-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Repaglinide Small molecule